← 返回

瘤内 CD8+ TIL(肿瘤浸润淋巴细胞)作为接受放化疗的鼻咽癌的预后预测因子

英文原题:Intratumoral CD8+ tumor-infiltrating lymphocytes as prognostic predictors in radio-chemoradiotherapy-treated nasopharyngeal carcinoma.

查看英文原题

Intratumoral CD8+ tumor-infiltrating lymphocytes as prognostic predictors in radio-chemoradiotherapy-treated nasopharyngeal carcinoma.

PubMed 2025/05/15(内容时间) Front Oncol Q2 · IF 3.4(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

我们的发现表明,瘤内 CD8+ TILs 可作为鼻咽癌可靠的预后生物标志物,其预后价值在局部晚期疾病患者中尤为显著。

中文摘要

TIL(肿瘤浸润淋巴细胞)对鼻咽癌(NPC)的预后价值已获确立,但NPC中CD4⁺和CD8⁺ TIL亚型的预后意义尚不明确。

收集214份经诊断为NPC的组织样本进行免疫组织化学染色。评估肿瘤内(肿瘤细胞巢内)和间质(肿瘤细胞巢周围间质)区域的CD4⁺和CD8⁺ TIL密度,并分析TIL密度与无进展生存期(PFS)和总生存期(OS)的相关性。

肿瘤内CD8⁺ TIL水平较高与疾病进展风险降低(HR 0.382;95% CI 0.178–0.819;P=0.013)及死亡风险降低(HR 0.265;95% CI 0.104–0.675;P=0.005)显著相关。尽管间质CD8⁺ TIL水平较高与更长的PFS和OS相关,但差异未达到统计学显著性(分别为P=0.114和P=0.079)。CD4⁺ TIL与PFS或OS均无显著相关性。多变量分析中,肿瘤内CD8⁺ TIL仍是PFS和OS的独立预后因素。亚组分析显示,在局部晚期患者中,较高的肿瘤内CD8⁺ TIL与PFS改善(HR 0.329;95% CI 0.129–0.843;P=0.021)及OS改善(HR 0.209;95% CI 0.064–0.681;P=0.009)显著相关。相反,在早期患者中,CD8⁺或CD4⁺ TIL均与PFS或OS无显著相关性。

研究结果提示,肿瘤内CD8⁺ TIL是NPC可靠的预后生物标志物,其预后价值在局部晚期患者中尤为明显。

展开英文摘要原文

The prognostic value of tumor-infiltrating lymphocytes (TILs) in nasopharyngeal carcinoma (NPC) has been established. However, the prognostic significance of CD4+ and CD8+ TIL subtypes in NPC remains unclear.

We collected 214 tissue samples diagnosed with NPC for immunohistochemical staining. The density of CD4+ and CD8+ TILs was evaluated in intratumoral (within tumor cell nests) and stromal (the surrounding stroma of tumor cell nests) areas. Correlations between TIL density and progression-free survival (PFS) and overall survival (OS) were analyzed.

High levels of intratumoral CD8+ TILs were significantly associated with reduced risk of disease progression (HR 0.382; 95% CI, 0.178-0.819, P = 0.013) and death (HR 0.265; 95% CI, 0.104-0.675, P = 0.005). Although high stromal CD8+ TIL levels were linked to higher PFS and OS, these differences did not reach statistical significance (P = 0.114 and P = 0.079, respectively). CD4+ TILs showed no significant correlation with PFS or OS. In multivariate analysis, intratumoral CD8+ TILs remained an independent prognostic factor for PFS and OS. Subgroup analysis revealed that in patients with locally advanced disease, high intratumoral CD8+ TILs were significantly associated with improved PFS (HR 0.329; 95% CI, 0.129-0.843, P = 0.021) and OS (HR 0.209; 95% CI, 0.064-0.681, P = 0.009). Conversely, in early-stage patients, neither CD8+ nor CD4+ TILs were significantly associated with PFS or OS.

Our findings suggest that intratumoral CD8+ TILs serve as a reliable prognostic biomarker for NPC, with their prognostic value particularly pronounced in patients with locally advanced disease.

论文信息

作者
Li X、Qiu X、Lin C、Liu Y、Wang Y、Tang L、Tong Y、Tang L
第一作者单位
Department of Pathology, Longyan First Affiliated Hospital of Fujian Medical University, Longyan, China.China
通讯作者单位
Department of Radiation Oncology, Longyan First Affiliated Hospital of Fujian Medical University, Longyan, China.China
期刊
Frontiers in oncology2025
原文标识
PubMed 40444078 · DOI 10.3389/fonc.2025.1551980